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Abstract
Background: 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) is a widely used entactogenic drug known
to impair cognitive functions on the long-run. Both hippocampal and frontal cortical regions have well established
roles in behavior, memory formation and other cognitive tasks and damage of these regions is associated with
altered behavior and cognitive functions frequently described in otherwise healthy MDMA users. Meanwhile, in
post-traumatic stress disorder (PTSD) patients seem to benefit from therapeutic application of the drug, where
damage in hippocampal cue extinction may play a role. The aim of this study was to examine the hippocampus,
frontal cortex and dorsal raphe of Dark Agouti rats with gene expression arrays (Illumina RatRef bead arrays) looking
for possible mechanisms and new candidates contributing to the consequences of a single dose of MDMA (15 mg/kg)
3 weeks earlier.
Results: The number of differentially expressed genes in the hippocampus, frontal cortex and the dorsal raphe were
481, 155, and 15, respectively. Gene set enrichment analysis of the microarray data revealed reduced expression of
‘memory’ and ‘cognition’, ‘dendrite development’ and ‘regulation of synaptic plasticity’ gene sets in the hippocampus,
parallel to the downregulation of CaMK II subunits, glutamate-, CB1 cannabinoid- and EphA4, EphA5, EphA6 receptors.
Downregulated gene sets in the frontal cortex were related to protein synthesis, chromatin organization, transmembrane
transport processes, while ‘dendrite development’, ‘regulation of synaptic plasticity’ and ‘positive regulation of synapse
assembly’ gene sets were upregulated besides elevated levels of a CaMK II subunit and NMDA2B glutamate receptor.
Changes in the dorsal raphe region were mild and in most cases not significant.
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Conclusion: The present data raise the possibility of new synapse formation / synaptic reorganization in the frontal
cortex 3 weeks after a single neurotoxic dose of MDMA. In contrast, a prolonged depression of new neurite formation in
the hippocampus is proposed by downregulations of members in long-term potentiation pathway and synaptic plasticity
emphasizing the particular vulnerability of this brain region and proposing a mechanism responsible for cognitive
problems in healthy individuals. At the same time, these results underpin benefits of MDMA in PTSD, where the drug
may help memory extinction.
Keywords: Ecstasy, Endocannabinoid, CB1, RhoGTPase, Serotonin, Gene expression, Microarray, Eph receptors, CaMKII,
NMDA2B
Background
Ecstasy (3,4-methylenedioxymethamphetamine, MDMA) is
an amphetamine derivative widely abused for its euphoric
and prosocial (entactogenic) effects in developed countries
[1, 2]. The acute indirect monoaminergic agonist effects of
MDMA are mainly mediated by an increase in serotoner-
gic, noradrenergic and dopaminergic neurotransmission of
the brain by reversing transmembrane transporter func-
tions, which are normally responsible for the uptake of neu-
rotransmitters from the synaptic cleft [1–3]. However, in
the long-run, a decrease in serotonergic markers was re-
ported in experimental animals and also in human users
suggesting a long-term selective vulnerability of the seroto-
nergic system [2, 4–6]. Functional deficits could also be ob-
served in humans and in rodents, e.g. impaired decision
making, sleep disturbances, increased anxiety and impulsiv-
ity levels, elevated aggression, learning and memory impair-
ments and depression [2, 5, 7–10]. In addition to the
selective damage observed in serotonergic neurons,
MDMA may also cause more wide-spread changes, like
production of toxic metabolites and free radicals or the dis-
ruption of local cerebral blood flow and glucose utilization,
which might cause alterations in the nutrition-supply of
neurons [4, 11–14].
The serotonergic projections in the mammalian brain,
the primary targets of MDMA’s effects in rats, originate
from the raphe nuclei in the brainstem. Dorsal (DR) and
median raphe nuclei innervate upper brain structures, in-
cluding the frontal cortical regions and the hippocampus
(HC) [15–18]. The frontal cortex (FC) plays major roles in
risk evaluation, executive functioning, and working mem-
ory, while its malfunctions may be associated with neuro-
psychiatric diseases [19–22]. At the same time, HC has a
pivotal role in contextual and hereby spatial memory for-
mation [18, 23], thus, all of the latter regions are candidates
for long-run functional consequences caused by MDMA.
Despite the observed serotonergic deficits, recent criti-
cism of these studies raised the possibility of the thera-
peutic application of MDMA. The Multidisciplinary
Association for Psychedelic Studies (www.maps.org) is in-
volved in studies investigating drug-assisted psychother-
apy with MDMA in post-traumatic stress disorder (PTSD)
patients. As a result, Mithoefer et al. demonstrated an
83% clinical response rate to psychotherapy with tolerable
side effects in the MDMA group compared with 21% in
the control group [24, 25]. However, mechanisms respon-
sible for these promising results in severe cases of PTSD
remain to be elucidated in the different brain regions that
are implicated in cognition and behavioral alterations.
Parallel to neuronal damage neuroprotective mecha-
nisms can occur and, later in time, recovery processes
also may begin. Heat-shock proteins (HSPs) can amelior-
ate the damage caused by cellular stress of different ori-
gin e.g. hyperthermia, ischemia, or excessive production
of free radicals [26]. Elevated levels of HSP27 in the FC
and HC 3 days after MDMA treatment was demon-
strated by Adori et al. and this elevation persisted until
at least 7 days in the HC but normalized in the FC by
this time [4]. Brain-derived neurotrophic factor (BDNF),
a well-characterized member of neurotrophic factors, is
involved in several processes maintaining central ner-
vous system (CNS) functions like dendritic arborization,
synaptogenesis and activity-dependent potentiation (for
review see [27]). A study elucidating MDMA’s effects on
BDNF mRNA expression reported ever increasing eleva-
tions in FC up to 7 days after MDMA administration
while in the HC a decrease was evident [28]. Investiga-
tion of MDMA’s long-term effects revealed that in the
parietal cortex BDNF protein levels peaked at 8 weeks
after an initial decline but in the HC no significant
change could be reported [29]. Differences were also
demonstrated on the long-run between HC and tem-
poral cortex in tryptophan hydroxylase levels, the 5-HT
synthesis enzyme, following binge or single-dose admin-
istration of MDMA [30]. All of the latter results suggest
different recovery capacities of the HC and FC, but the
detailed biochemical mechanisms responsible for these
differences remained so far less investigated at later time
points. We speculated that these consequences might be
already visible at 21 days following a single dose of
MDMA thus we performed our analysis 3 weeks after
drug administration to investigate both recovery pro-
cesses and downstream mediators of already mentioned
functional effects at this time point [5, 7].
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Studies examining transcriptional changes following
MDMA administration are scarce, only few reports evaluated
alterations in mRNA levels of genes which were assumed to
be related to MDMA effects (see e.g. [5, 28, 31–33]).
Thus, the aim of this study was to identify downstream
transcriptional consequences of MDMA (which may be
related to functional alterations of the drug) and to find
possible new targets of regulatory mechanisms by using
large-scale gene expression profiling in the HC, FC, and
DR regions of Dark Agouti (DA) rats 21 days after a
single-dose MDMA administration. Additionally, we also
addressed whether signs of functional recovery on the mo-
lecular level can occur in the FC and HC and if so,
whether they differ in quality or quantity in these two re-
gions. In order to achieve our goals we used a dosage regi-
men of 15 mg/kg in the DA rat strain, which was utilized
for the following reasons: 1) it is a commonly used strain
in MDMA research, 2) DA rats are more similar to each
other compared to other rat strains, thus, on a
genome-wide scale our results remain more comparable
with other experiments, 3) we were able to compare
current results with those from our previous experiments
with the same strain and same dosage regimen.
Results
General overview of gene expression alterations
Comparison of the gene expression profiles showed 615
differentially expressed genes in the MDMA treated
group compared to the saline control (minimum prob-
ability of positive log ratio [MinPplr] < 0.001). From 155
significant genes in the FC region 66 were up- and 89
downregulated. In the HC region 481 genes showed al-
tered expression, 171 and 310 genes were up- or down-
regulated, respectively. Only 14 unique genes were
altered in the DR region, 11 showed elevated expression
and the remaining 3 showed a decrease compared to the
control group. All genes emphasized in the chapters
below were selected by individual considerations of
MDMA’s known effects and related literature data. For
full results see Additional file 1: Table S1.
The gene set enrichment analysis (GSEA) revealed 55,
18 and 1 differentially regulated gene sets in the FC, HC
and DR regions, respectively.
Frontal cortex
Differentially expressed genes
MDMA caused a significant overexpression of long-term
potentiation (LTP) pathway genes (Camk2g and Camk1g)
and the ionotropic glutamate receptor, NMDA2B
(Grin2b). The alpha subunit of the heat shock protein 1
(Hspca, HSP90α) and heat shock factor 2 (Hsf2) were
downregulated, similarly to high-affinity glial glutamate
transporter (Slc1a3) (See Table 1 and Additional file 1:
Table S1 for all significantly altered genes).
Gene set enrichment analysis
Altogether 55 gene sets were differentially enriched in
the FC after the single-dose MDMA treatment, contain-
ing both our literature-based, individually chosen (Add-
itional file 2: Table S2) and Msig DB C5 gene sets.
Additionally, we used GSEA network analysis on signifi-
cantly enriched GO terms to determine biologically rele-
vant processes shown in Table 2.
The biological process with the most prominent alter-
ations contained 21 significantly dysregulated gene sets re-
lated to protein synthesis and protein localization within
the neurons, and 10 significantly enriched gene sets were
involved in transport processes. All of these 31 gene sets
were, without exception, downregulated in the FC region,
together with gene sets responsible for chromatin main-
tenance. The dendrite and synapse development gene sets
were upregulated 3 weeks after MDMA administration
(Table 2, in all cases, p < 0.05, and FDR < 0.25, see Add-
itional file 3: Table S3 for detailed and full results).
We also used in silico GSEA network analysis (Fig. 1)
on significantly enriched gene ontology (GO) terms, which
represents functional connectivity and was applied to de-
termine biologically relevant processes shown in Table 2.
Hippocampus
Differentially expressed genes
Changes in major hippocampal neuroplasticity related
pathways included reductions in glutamatergic GRIN2A
(Grin2a) and AMPA3 (Gria3) mRNA levels, parallel
with downregulations in a variety of LTP pathway mem-
bers, like calcium/calmodulin dependent protein kinase
(CaMK) II genes (Camk2g, Camk2b), kalirin, (Kalrn) and
EphA4 (LOC316539), Epha5 and Epha6 receptors, mem-
bers of ephrin signaling. Accordingly, an inhibitor of the
CaMK II (Camk2n2) was upregulated along with a
GABA-A receptor subunit (Gabre). The mRNA levels of
Atp2b3, Atp2b1 calcium transporting ATP-ases and
Slc5a3, an inositol transporter was also decreased. Some
of the voltage-gated potassium transporter genes (Kcnd2,
Kcnc2) were also downregulated and type 1 cannabinoid
receptor (Cnr1, CB1) showed decreased levels in HC,
too. (See Table 1 and Additional file 1: Table S1 for all
significantly altered genes).
Gene set enrichment analysis
The GSEA analysis revealed altogether 18 differentially rep-
resented gene sets in the HC region, including both the
Msig DB C5 gene set database and individually chosen gene
sets based on the literature (see Additional file 2: Table S2).
Two particularly important gene sets, ‘memory’ [GO:000
7613] and ‘cognition’ [GO:0050890] were underexpressed
in HC samples and multiple gene sets related to the mo-
lecular function of kinases were also downregulated. Other,
negatively influenced processes included synaptic plasticity
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Table 1 Selection of significantly altered genes by single-dose MDMA treatment in the different brain regions
MinPplr Fold Change
(on log2 scale)
Frontal Cortex
Camk2g Calcium/calmodulin-dependent
protein kinase II gamma
0.000127 0.900
Camk1g Calcium/calmodulin-dependent
protein kinase I gamma
0.000174 0.383
Grin2b Glutamate receptor, ionotropic,
NMDA2B (Grin2b)
0.000395 0.448
Hspca Heat shock protein 90α 0.000677 −0.398
Slc1a3 Solute carrier family 1
(glial high affinity glutamate
transporter), member 3
0.000417 −0.724
Hippocampus
Gria3 Glutamate receptor, ionotropic,
AMPA3
5.23E-05 −0.916
Grin2a Glutamate receptor, ionotropic,
N-methyl D-aspartate 2A
5.42E-08 −1.610
Camk2g Calcium/calmodulin-dependent
protein kinase II gamma
1.46E-08 −1.451
Camk2b Calcium/calmodulin-dependent
protein kinase II beta
1.02E-08 −1.751
Kalrn Kalirin, RhoGEF kinase 2.69E-05 −0.419
LOC316539 Eph receptor A4 1.82E-05 −0.729
Epha5 Eph receptor A5 3.29E-09 −1.065
Epha6 Eph receptor A6 7.39E-05 −0.484
Camk2n2 Calcium/calmodulin-dependent
protein kinase II inhibitor 2
3.44E-06 0.345
Gabre Gamma-aminobutyric acid A
receptor, epsilon
0.000525 0.268
Atp2b3 ATPase, Ca++ transporting, plasma
membrane 3
2.41E-12 −0.567
Atp2b1 ATPase, Ca++ transporting, plasma
membrane 1
1.16E-05 −0.863
Slc5a3 Solute carrier family 5 (inositol
transporters), member 3
9.94E-10 −1.356
Kcnd2 Potassium voltage gated channel,
Shal-related family, member 2
7.56E-07 −1.476
Kcnc2 Potassium voltage gated channel,
Shaw-related subfamily, member 2
6.11E-07 −0.905
Cnr1 Cannabinoid receptor 1 3.1E-06 −0.793
Dorsal Raphe
Slc6a5 Solute carrier family 6
(neurotransmitter transporter,
glycine), member 5
0.000153 1.143
Hsd11b1 Hydroxysteroid 11-beta
dehydrogenase 1
1.19E-08 0.450
Dao1 D-amino acid oxidase 0.000384 0.451
This table summarizes the genes significantly (minimum probability of positive log ratio (MinPplr) < 0.001) altered in the frontal cortex (FC), hippocampus
(HC) and dorsal raphe (DR) of Dark Agouti (DA) rats after a single-dose 3,4-methylenedioxymethamphetamine (MDMA) treatment (15 mg/kg,
intraperitoneal) 3 weeks earlier. The genes were selected based on literature data and individual considerations, for all the significantly changed genes
see Additional file 1: Table S1. See text for further details
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and dendrite / synapse development and the regulation of
glutamatergic neurotransmission (Table 3, in all cases, p <
0.05, and false discovery rate (FDR) < 0.25, see Additional
file 3: Table S3 for detailed and full results). Figure 2 sum-
marizes the main findings of the gene set analyses in a net-
work form based on the GSEA network analysis.
Dorsal raphe
Differentially expressed genes
In the DR region the glycine neurotransmitter trans-
porter (Slc6a5), the D-amino acid oxydase (Dao1) and
the 11-beta-hydroxisteroid dehydrogenase (Hsd11b1,
11β-HSD1) genes were upregulated among others (See
Table 1 and Additional file 1: Table S1 for all signifi-
cantly altered genes).
Gene set enrichment analysis
In the region only one gene set, namely ‘caspase activa-
tion’ [GO:0006919] was significantly downregulated after
the single-dose MDMA treatment. No upregulated gene
sets could be observed (in all cases p < 0.05, and FDR <
0.25). The full results of the GSEA analysis in the DR
region are shown in Additional file 3: Table S3.
Heatmap analysis
The heatmap (Fig. 3) shows genes after two-way hier-
archical clustering comparing their expression levels
among all three regions. It provides a different insight
into the transcriptional changes after MDMA treatment.
In the HC region nearly all of the genes were downregu-
lated. In contrast, most of those genes that were down-
regulated in the HC were found to be upregulated in the
FC, suggesting marked differences between the two re-
gions. Changes in the DR were scant independently of
alterations in the other two regions.
Discussion
In this study we evaluated the transcriptional conse-
quences 3 weeks after a single neurotoxic dose of MDMA
in DA rats with gene expression arrays in three different
brain areas. The FC region exhibits wide-scale negative
changes in basic anabolic and transport processes and the
upregulations of the ‘dendrite development’, ‘regulation of
synaptic plasticity’ and ‘positive regulation of synapse as-
sembly’ gene sets suggest a partial new synapse formation/
synaptic reorganization in this region on the transcrip-
tional level. MDMA’s effects indicate alterations in cogni-
tion and memory related processes with the possible
involvement of the LTP pathway, CB1 and Eph receptors
in the HC. These differences between the FC and HC
point to markedly different transcriptional responses of
these two brain regions 3 weeks after a single dose
MDMA administration.
Frontal cortex
While alterations in expression of 5-HT markers in cortical
regions are well-defined, studies examining other effects of
MDMA on gene expression are scarce. Thiriet et al. exam-
ined 1176, toxicology-related genes in adult Sprague-Dawley
rats and followed expression patterns up to 7 days after a
20 mg/kg single-dose MDMA administration [33]. They
found nerve growth factor alterations and suggested cyto-
skeletal reorganization while in another study, Fernandez-
Castillo et al. emphasized neuroinflammatory responses in
MDMA-effects 8 h after repeated-administration in adult
mice [32]. Martinez-Turillas et al. investigated BDNF aug-
mentations in the FC region of Wistar rats up to 7 days after
drug administration [28]. In our present study we examined
gene expression patterns longer time (3 weeks) after a single
neurotoxic dose of MDMA in the DA rat strain and found
no overlap with previous transcriptomic investigations prob-
ably because of the different time point examined. We re-
port wide-scale downregulation of genes involved in
chromatin organization, nucleocytoplasmic transport,
ribosome-related functions, protein synthesis/folding and
transmembrane transport processes in the FC region (Table
2). It seems reasonable that the observed changes are
long-term consequences of the acute general neurotoxic
processes, like toxic metabolite formation, hyperthermic
effect or free radical production or impairment in the auto-
regulation of cerebral blood flow [4, 11–14, 34–38]. The
latter is even further supported by the upregulation of the
response to hyperoxia gene set.
Motor regions in the FC are targets of thalamical in-
puts and contribute to motor system functions [39].
Studies in DA rats with the same MDMA administration
Table 2 Biologically Relevant Processes with Enriched Gene
Sets in the Frontal Cortical Region
Biological Process Number of Enriched Gene
Sets Related to the Process
Direction
Protein synthesis and
localization
21
Transmembrane transport 10
Nucleocytoplasmic transport 7
Cell growth 6
Others 4
Chromatin maintenance 3
Dendrite and synapse
development
3
Oxidoreductase activity 2
This table summarizes the biological processes significantly altered in the frontal cortex
(FC) of Dark Agouti (DA) rats after a single-dose 3,4-methylenedioxymethamphetamine
(MDMA) treatment (15 mg/kg, intraperitoneal) 3 weeks earlier. The processes were
created based on the network analysis of gene set enrichment x analysis and
individual considerations. All significantly enriched GO terms are included in one of the
processes. Downward arrows represent down-, upward arrows represent
upregulations. In some of the biological processes both up- and downregulated
gene sets were present (mixed up- and downward arrows). See text for
further details
Petschner et al. BMC Genomics  (2018) 19:580 Page 5 of 17
protocol like in the recent experiment indicated chronic
changes in motor activity [40–42]. Additionally, Kara-
georgiou et al. reported alterations in right supplemen-
tary motor area activation in human MDMA users on
fMRI recordings [43]. Our results might reflect molecu-
lar changes in the FC that may relate to these observa-
tions on a functional level.
As from another functional perspective FC and pre-
frontal cortical regions (PFC) are not only responsible
for motor functions, but are also closely related to differ-
ent cognitive tasks, e.g. working memory, goal-directed
behavior, and executive functions in rats [20, 44–46]. In
our experiment FC samples contained regions from pri-
mary and secondary (supportive) motor cortices princi-
pally and likely some parts of PFC [46]. Thus, inhibition
of certain biosynthetic processes found in the present
study might be distinctly involved in the cognitive de-
cline of heavy MDMA users.
We have previously demonstrated that HSP90 staining
is not influenced by MDMA either 3 days or 1 week
after administration in DA rats with the same adminis-
tration protocol [4]. The downregulation of Hspca gene
mRNA encoding for HSP90α, therefore, is surprising
and may indicate changes later in time that might be
Fig. 1 Network Analysis of the GSEA Results in the Frontal Cortex. The network shows significantly (nominal p < 0.05, false discovery rate < 0.25) enriched
gene ontology (GO) terms in the gene set enrichment (GSEA) analysis in the frontal cortex (FC) of Dark Agouti rats 3 weeks after a single-dose (15 mg/kg,
intraperitoneal) 3,4-methylenedioxymethamphetamine (MDMA) administration. Blue and red circles represent down- and upregulation of the associated
GO terms, respectively. The size of the nodes is proportional with the number of genes in the GO term and the thickness of the grey edges represents
the number of common genes between two GO terms, if any. Most of the processes in the FC were downregulated. The cellular biosynthetic process
and establishment of cellular localization GO terms are in central positions of two different groups while chromosome and chromatin organization, and
transmembrane transport processes form the third and fourth group of tightly related, downregulated gene sets. These alterations suggest a general
neurotoxic effect while the upregulation of gene sets related to synapse formation raises the possibility of a parallel running recovery process. The
expression of the only immunologically related GO term was attenuated. See text for further details
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triggered by Hsf2 (also downregulated in the present ex-
periment) able to bind promoter regions of Hspca [47].
Nevertheless, further studies are definitely required to
unravel the exact roles of these factors in the FC of DA
rats after single-dose MDMA administration.
A possible recovery mechanism on a network level
marked by the upregulation of LTP members, like CaMK
subunits Camk2g and Camk1g and the ionotropic glutam-
ate receptor, NMDA2B (Grin2b), is suggested. Activation
of CaMK II is both necessary and sufficient for LTP induc-
tion under physiological circumstances and it remains one
of the most important factors in this process and, hence,
in cognition itself [48]. The preceding Ca-influx which
normally activates CaMK II is triggered by activation of
NMDA-type glutamate receptors and, while different
NMDA subunits may regulate different behaviors, all are
involved in LTP [48, 49]. Physiologically, after elevations
Fig. 2 Network Analysis of the GSEA Results in the Hippocampus. The network shows significantly (nominal p < 0.05, false discovery rate < 0.25)
enriched gene ontology (GO) terms in the gene set enrichment (GSEA) analysis in the hippocampus (HC) of Dark Agouti rats 3 weeks after a
single-dose (15 mg/kg, intraperitoneal) 3,4-methylenedioxymethamphetamine (MDMA) administration. Blue circles represent the downregulation
of the associated terms, while red circles would represent upregulations. The size of the nodes is proportional with the number of genes in the
GO term and the thickness of the edges between lines represents the similarity coefficient. All processes in the HC are downregulated, and two
well characterized groups of processes emerge. On one hand the processes related to cognition and memory, e.g. regulation of synaptic plasticity,
dendrite development and regulation of glutamatergic synaptic transmission gene sets form a diverse group. On the other hand the processes related
to kinase activity form another network. See text for further details
Table 3 Biologically Relevant Processes with Enriched Gene
Sets in the Hippocampal Region
Biological Process Number of Enriched Gene
Sets Related to the Term
Direction
Protein Phosphorylation 4
Dendrite and synapse
development
4
Synaptic plasticity 4
Transmembrane transport 2
Others 2
Memory, cognition 2
This table summarizes the biological processes significantly altered in the
hippocampus of Dark Agouti rats after a single-dose 3,4-
methylenedioxymethamphetamine (MDMA) treatment (15 mg/kg, intraperitoneal)
3 weeks earlier. The processes were created based on the network analysis of gene
set enrichment analysis and individual considerations. All significantly enriched GO
terms are included in one of the processes. Downward arrows represent
downregulations. See text for further details
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in intracellular Ca2+ concentrations, which render it into
active conformation, CaMK II phosphorylates multiple
targets within the neurons on their serine/threonine resi-
dues and ultimately recruits AMPA receptors into post-
synaptic dendritic spine membranes accompanied by
morphological changes of these membranes through
guanine nucleotide exchange factors that activate Rho
GTPases (RhoGEFs) [48]. According to our recent under-
standing, through these steps synapses are markedly sensi-
tized for glutamate-induced depolarization, which is, in
essence, LTP and is considered as the basic mechanism of
cognitive functions on neuronal levels. LTP, while mainly
associated with HC has important roles also in motor re-
gions, PFC, and neocortical regions and it influences skill
learning and executive functions alike [50, 51]. Our results
indicate that the frontal cortical region reacts differently
to a previous, single-dose MDMA challenge than HC in
DA rats (see in Hippocampus chapter). While individual
cells may show impaired biosynthetic processes, these al-
terations seem to be compensated on a network level by
the possible strengthening of neuronal connections, a
mechanism which provides the possibility of functional
restoration following injuries of the central nervous sys-
tem [52]. These conclusions on the gene level are partially
underpinned by the GSEA, since gene sets related to den-
drite and synapse development were upregulated. While
connectivity may be enhanced, indication for enhanced
LTP is provided only on a gene level (elevated Camk2g,
Camk1g and Grin2b), and we have to note that gene sets
could not unequivocally confirm such processes.
In summary, the downregulation of almost 50 gene sets
related to biosynthetic processes in the FC may reflect
consequences of general neurotoxic effects not related to
specific pathways (see Fig. 4). At the same time, the upreg-
ulation of the gene set responsible for dendrite develop-
ment in this brain region may point to a starting recovery
process/synaptic reorganization and could be a sign of a
compensatory mechanism ameliorating MDMA’s acute ef-
fects 3 weeks after the administration in DA rats.
Hippocampus
In the HC region we report downregulations in CaMK II
subunits, Camk2g and Camk2b and upregulation of an in-
hibitor of CaMKs parallel with decreased level of a
Fig. 3 Two-way hierarchical clustering of representative genes
selected from all three brain regions. Genes modulated more than
1.5 or less than 0.5 are clustered (Euclidean distance, average
linkage) into the heatmap from all three brain regions (hippocampus
[HC], frontal cortex [FC] and the dorsal raphe [DR]) of Dark Agouti
rats 3 weeks after a single-dose of (15 mg/kg, intraperitoneal)
MDMA. The brain regions are unequivocally separated by this
analysis, suggesting markedly different effects of MDMA in the
different regions. See text for further details
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regulatory subunit of NMDA glutamate receptors, Grin2a.
Moyano et al. observed attenuated levels of CaMK II after
1 week cessation following an MDMA treatment protocol
upon a repeated administration, but could not demon-
strate altered levels of CaMK II or NMDA-receptor sub-
units without the acute challenge, hence, concluded that
MDMA cannot cause chronic alterations in CaMK II or
NMDA-subunit levels in the HC [53]. We show that later,
namely after 3 weeks, CaMK II and Grin2a show de-
creased mRNA levels. Chronic downregulations of CaMK
II and an NMDA channel mRNAs may mark central alter-
ations that can ultimately lead to losses in cognitive per-
formance via the disruption of LTP. In the present study
decreased expression of Ca-transporters, like Atp2b3 and
Atp2b1, further support the notion of altered calcium
homeostasis that may affect CaMK II activation, while
downstream effectors of the LTP pathway, AMPA3 and
kalirin, a RhoGEF kinase, were also significantly downreg-
ulated. Taken together, besides CaMK II and Grin2a,
mRNA levels of several components necessary for proper
Fig. 4 A Schematic Representation of MDMA’s Sites of Action in Frontal Cortex. This figure summarizes the effects of a single-dose (15 mg/kg,
intraperitoneal) 3,4-methylenedioxymethamphetamine (MDMA) administration 3 weeks earlier on the frontal cortex (FC) of Dark Agouti rats and
provides a hypothetical framework. On one hand, neurons of neuronal networks within this region seem to suffer wide-scale downregulations (marked
with numbers in blue circles in the neuron on the right hand side) in their basic functions, like transport processes, chromatin maintenance and protein
synthesis and localization, as a possible consequence of MDMA’s free radical producing and hyperthermic effects. Since the downregulated processes
would be important mechanisms for neuronal survival, neuronal networks might suffer from the loss of basic functions of individual cells. As compensation
on a network basis, upregulations of the long-term potentiation (LTP) genes (like Camk2g calcium/calmodulin dependent kinase subunit and NMDA-
receptor subunit Grin2b, marked by numbers in red circles in the neuron on the left hand side) along with pathway level upregulations suggest a possible
ongoing recovery (as shown in bottom right). Please, note, changes represent mRNA level up/downregulations, no protein levels were measured
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LTP are negatively influenced 3 weeks after single-dose
MDMA administration in the used rat strain. Further-
more, results from GSEA support the gene level data
showing downregulation of protein phosphorylation,
memory, cognition, synaptic plasticity and synapse/den-
drite development gene sets, correlates of the mRNA al-
terations on a pathway level (though LTP pathway directly
remained non-significant, see Fig. 2 and Additional file 3:
Table S3). Thereby, HC shows a contrast to FC, where
some genes of the LTP pathway showed opposite changes.
Such differences between the HC and FC suggest that dif-
ferent memory types with different relative involvement of
these regions may show different responses to the drug.
Indeed, a functional study investigating such differences
following binge administration of MDMA, reported rats
learning working-memory related tasks (mainly FC medi-
ated) faster on the long-run compared to spatial reference
memory (mainly HC mediated) in an 8-arm radial maze
challenge [54]. In summary, these results indicate that the
MDMA-caused lasting cognitive impairments in humans
and experimental animals [2, 5, 8–10, 55, 56] may be par-
tially consequences of transcriptional downregulations in
essential elements of the CaMK II-mediated pathway in
the HC at a chronic time point after use.
In this region we also show decreased mRNA levels of
EphA4, EphA5 and EphA6 receptors. These membrane-an-
chored receptors only exert their actions upon direct
cell-cell contact and, after binding, both the receptor and
the similarly membrane-anchored ligand start intracellular
signaling processes [57]. Eph receptors are suggested to be
involved in the development and maintenance of HC and
its cognitive functions through modulating synapse forma-
tion and glutamatergic LTP [58]. Simón et al. demonstrated
that reductions in HC EphA4 levels preceded the develop-
ment of attenuated object recognition and spatial memory
in a mouse model of Alzheimer-disease [59, 60], while
Epha6 KO mice showed impaired memory using a fear
conditioning training paradigm [61]. Although in compari-
son with EphA4 and EphA6, EphA5 is weakly labelled
under physiological conditions in the HC, it may also be ne-
cessary for proper neuronal projections in the region [62].
Another gene downregulated in the current setup was
the CB1 receptor. Nawata et al. also investigated CB1 re-
ceptor mRNA levels in the HC regions of mice up to
7 days following the cessation from repeated MDMA ad-
ministration and they reported an increase 7 days, but
not 1 day after last treatment [56]. CB1 receptors are
important components in suppression of excitatory im-
pulses in the HC through inhibition of presynaptic
neurotransmitter release [63]. It is accepted that sup-
pression of synaptic glutamate levels in the HC by can-
nabinoid agonists cause impairments in cognitive
functions and, accordingly, antagonists may improve
them [64]. Indeed, Nawata et al. also showed that a
cannabinoid antagonist was able to ameliorate the
MDMA induced cognitive impairments at 7 days after
withdrawal from the drug suggesting that elevated CB1
levels may be important in this effect [56]. Here we re-
port downregulations, which suggest alternating tem-
poral patterns or species differences of this receptor
after MDMA use and, hence, application of CB1 antago-
nists at later time points may have different conse-
quences, at least in DA rats. Nevertheless, increased
intracellular Ca2+ levels, a result of NMDA channel acti-
vation could directly induce endocannabinoid release in
HC neurons and, thus, one may speculate that decreased
Ca2+ levels (as a consequence of Grin2a downregulation)
might be the sources for downregulations of CB1 recep-
tors observed in the current paradigm [65].
Potassium channels play important roles in the main-
tenance of intracellular ion concentrations, the excitability
of the neurons and in LTP, where long-term adaptations
in excitability occur. The Kcnd2 gene encodes for a
Shal-related potassium channel, Kv4.2, which is respon-
sible for A-type K+ currents in hippocampal pyramidal
neurons [66]. Varga et al. demonstrated that CaMK II acti-
vation induces elevations in functional cellular Kv4.2 pro-
teins, thus, the downregulations of Kv4.2 mRNA in our
study might reflect the attenuation in CaMK II functions
discussed previously [67], along with decreased Kcnc2
levels encoding the Kv3.1b potassium channel [68].
As we have only investigated one dose of MDMA and
only at 3-weeks after administration, our results are less
generalizable. However, we would like to point to a pos-
sible connection between our results on a transcriptomic
level and the recent successful clinical application of the
drug in combination with psychotherapy in PTSD pa-
tients [25]. While in otherwise healthy human individ-
uals the alterations discussed above can be detrimental
on cognitive functions, in disease, loss of negative mem-
ory clues may be beneficial [69]. In PTSD it has been
long proposed that dysfunctions in memory extinction
may be involved in the maintenance of the symptom-
atology [70]. If our results can be extrapolated on an in-
terspecies scale and onto the protein level by subsequent
confirmatory analyses, they may represent molecular
mechanisms through which MDMA may induce extinc-
tion of negative clues in HC circuitries and could benefit
PTSD patients.
Taken together, MDMA, 3 weeks after its use in a
single dose, caused decreased mRNA levels of major
components of the LTP pathway, ephrin signaling and
CB1 receptors accompanied by downregulations in
memory, cognition, synaptic plasticity and synapse/
dendrite development gene sets in HC of DA rats
(Fig. 5). Our results indicate that a central region of
cognitive functioning, the HC, may be particularly
vulnerable for MDMA’s toxic effects in DA rats.
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Dorsal raphe
The changes in the DR region were mild in line with our
previous results suggesting that MDMA-caused damage
to these neurons are restricted to serotonergic axon ter-
minals instead of neuronal cell bodies directly [71]. The
caspase activation gene set significantly changed in the
present study was not supported by individual genes, or
other gene sets related to apoptotic processes. The up-
regulation in 11β-HSD1 mRNA level might suggest a
possible role of the hypothalamic-pituitary-adrenal axis
Fig. 5 A Schematic Representation of MDMA’s Sites of Action in Hippocampus. This figure summarizes the effects of a single-dose (15 mg/kg,
intraperitoneal) of 3,4-methylenedioxymethamphetamine (MDMA) 3 weeks earlier on hippocampal neurons in Dark Agouti rats. White circles
represent molecular events explained in this legend. Based on current knowledge, neuronal long-term potentiation (LTP) would be initiated by
glutamate release from synaptic vesicles (1) and their binding to NMDA-type glutamate receptors, which after activated, let Ca2+ flow into the
cells (2). The elevated intracellular Ca-levels, on one hand, cause endocannabinoid synthesis acting as a negative feedback mechanism via
cannabinoid 1 (CB1) receptors (3), while on the other hand, activate calcium/calmodulin dependent kinase II (CaMK II) and induce autoactivation
of the enzyme (4). The active CaMK II molecules phosphorylate intracellular targets, thereby activating Rho GTPases (5) to induce changes in
synaptic membrane morphology (6) and, thereby, let AMPA glutamate receptors be expressed in postsynaptic membranes (7). The newly
recruited AMPA receptors may react to presynaptic glutamate release causing elevated excitability upon repeated stimuli and a strengthening of
synaptic transmission. Downregulations caused by the single-dose administration are marked by blue numbers and show that besides of
decreased mRNA levels found in our study in the subunits of the LTP-members (which was supported by downregulations in regulation of
synaptic plasticity, cognition and memory gene sets), the drug also induced downregulation in Eph receptors, which may be responsible for
direct cell-cell contacts in synapses. These changes indicate that the connectivity and thus, hippocampal neuronal network functions might be
damaged as a consequence of the administration of the drug. Please, note, changes represent mRNA level up/downregulations, no protein levels
were measured. See text for further details
Petschner et al. BMC Genomics  (2018) 19:580 Page 11 of 17
and glucocorticoids in MDMA’s long-term conse-
quences, an effect also proposed by others [72, 73].
11β-HSD1 is responsible for the conversion of glucocor-
ticoids into active form. Chronically elevated glucocorti-
coids were shown to be involved in aging and cognitive
decline and it has been shown that 11β-HSD1 may in-
duce such processes [74]. Since its expression was con-
firmed in the brainstem [75], 11β-HSD1 may be an
interesting topic for further research in the region.
Otherwise, the DR region seems to be mostly unaffected
3 weeks after a single-dose of MDMA administration in
DA rats.
Limitations
In the present study we have not elucidated the temporal
patterns of the mRNAs. Further studies are needed ad-
dressing the time course of described alterations to elicit
causative relations of these transcriptional processes in de-
tail, especially, since some alterations in HC seem to be
highly time-dependent and may influence therapeutic in-
terventions of MDMA-induced cognitive changes.
We could not confirm the decreased expression of seroto-
nergic markers in the present study. Both serotonin trans-
porter and tryptophan hydroxylase mRNA levels were
unaltered in the treatment group, which is in conflict with
previous results: well established prolonged serotonergic de-
pletion and decreased expression of serotonergic markers in
both protein and mRNA levels after MDMA-treatment was
demonstrated by our group earlier [4, 5]. Here we can as-
sume that collection of DR samples was not precise enough
and as we did not apply laser capture microdissection in this
case, significant amount of surrounding tissue was perhaps
cut out together with the DR and it may result a bias in the
measurement of serotonergic markers. Notably, the decrease
of serotonin transporter expression, measured by quantita-
tive in situ hybridization, was approximately 20% in the
same animal model 3 weeks after the MDMA treatment,
compared to the control level, and this moderate alteration
was significant only in case of the fine measurement of grain
densities of individual cells but not with the measuring of
the autoradiography signal on film [5].
On the other hand, microarray method has well-known
drawbacks, when compared to polymerase chain reaction
(PCR) methods or in-situ hybridization used in our earlier
papers. Namely, limited amount of probes on the micro-
array may result in smaller fold change values. In addition,
shorter oligomers used can result in more mismatch
hybridization, which can overcome smaller changes in
gene expressions, like that in the case of serotonin trans-
porter. However, for this very reason we assume that the
results presented here, with our significance criterion, are
robust enough to overcome this bias.
We did not find alterations in the Bdnf gene expres-
sion, which is in agreement with our previous study
where we demonstrated that (after a slight transient
acute decrease) BDNF protein level was increased only
8 weeks after same MDMA dosage regimen in same rat
strain [29].
Though members of LTP pathway were downregu-
lated, we could not demonstrate a downregulation in the
pathway itself by GSEA in HC. GSEA examines all of
the genes of a certain pathway in the ordered list of
genes (based on t-statistics) between the experimental
groups. Significance of complete pathways therefore de-
pends on all of the genes annotated to a given set. This
could mean that other members, except those which
were significant, in the LTP pathway remained mostly
unchanged. However, on one hand, our present know-
ledge about CaMK II indicates that it can be solely re-
sponsible for the induction of LTP [48] and, on the
other, related pathways (e.g. cognition and memory sets)
were significant, therefore, we think this discrepancy is
less of an importance.
We must also note the major limitation of transcrip-
tomic studies, namely, mRNA levels do not necessarily
reflect to the corresponding protein levels. At the same
time, we have to point out that recent studies demon-
strated mRNA levels as important regulators of protein
levels [76, 77].
Finally, we also have to note that strain selection could
have influenced the results because DA rats might be
more prone to autoimmune neuroinflammation and glial
activation [78], can have altered reactivity in the dopamin-
ergic (and thus reward) system [79], may show elevated
serotonergic neurotoxicity after MDMA [80] and DA rats
are considered poor or intermediate metabolizers at
CYP2D1 corresponding the human CYP2D6 that is impli-
cated in MDMA metabolism [80]. While these effects may
have influenced our observations, there is currently no
direct proof that our findings would be substantially al-
tered and conclusions limited by using this strain.
Conclusion
We performed a genome-wide evaluation of transcrip-
tional changes 3 weeks after a single-dose of MDMA in
DA rats. The downregulated pathways in the FC were re-
lated to the basic mechanisms of the cell functionality in
the absence of specific markers of certain pathways. Up-
regulation of ‘dendrite development’, ‘regulation of synap-
tic plasticity’ and ‘positive regulation of synapse assembly’
gene sets raise the possibility of new synapse formation/
synaptic reorganization mechanisms in the region. All of
these results point out to a starting reinstatement of the
neuronal pathways and connections in the FC 3 weeks
after a 15 mg/kg dose of MDMA. The HC region showed
markedly different changes. Our data highlight decreased
CaMK II, glutamatergic, Eph receptor and CB1 mRNA
levels as potential downstream mediators of MDMA in
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the HC. In addition, GSEA showed downregulated ‘cogni-
tion’ and ‘memory’ gene sets similarly indicating decreased
functionality of LTP and glutamatergic pathways. These
results provide further molecular biological information
on the transcriptional level, which may underpin the
well-known cognitive deficits following MDMA use in
humans and animals as well as might indicate a possible
mechanism by which the drug can help extinction of
negative memory clues in PTSD patients.
Methods
Animals
Altogether 21 male DA rats (Harlan, Olac Ltd., Shaw’s
Farm, Blackthorn, Bicester, Oxon, UK) aged approxi-
mately 8 weeks (weighing 152 ± 3,58 g (SEM) at the be-
ginning of the experiment) were used. The animals (four
per cage) were kept under controlled environmental
conditions along the whole experiment (temperature 21
± 1 °C, humidity: 40–50%, 12 h light-dark cycle starting
at 6:00 a.m.) and food and water were available for them
ad libitum.
Drug administration and experimental design
(±)3,4-methylenedioxymethamphetamine (Sanofi-Synthela-
bo-Chinoin, Hungary, purity > 99.5%) was dissolved in 0.9%
NaCl (SAL) at an equivalent dose of 15 mg/kg free base
and was administered intraperitoneally (i.p.) in a volume of
1 ml/kg. The dose of MDMA was selected based on the in-
terspecies scaling Dhuman ¼ DanimalðWhumanWanimalÞ
0:7
, where D are
doses in mg and W are weights in kg [81]. By using Wanimal
= 0.152 kg, D
animal
= 15 mg/kg * 0.152 kg, and Whuman =
70 kg, our administration protocol results in a dose of
166.8 mg human dose [81] that is in a similar range as in a
recent clinical study (187.5 mg) on MDMA’s therapeutic ef-
fects [25] and can be found in purer MDMA tablets for
recreational use [2, 82].
For control animals SAL was used i.p. in equivalent vol-
umes (1 ml/kg). The MDMA-treated and control groups
consisted of 11 and 10 animals, respectively, and were ran-
domly assigned to each group. Vehicle-containing Alzet
2001 osmotic minipumps (Durect Corp., CA, USA) were
inserted under the skin for all animals. The rats were
sacrificed 3 weeks after the injections.
RNA extraction and sample preparation
Three weeks after MDMA or vehicle injections rats were
killed quickly by decapitation. The brains were removed,
approximately 2 mm thick coronal sections were cut and
the HC, FC and DR regions were dissected according to
Paxinos and Watson ([83], dorsal HC: from bregma −
2.5 mm to − 4.5 mm; FC: from bregma + 1.7 to − 0.3 mm;
DR: from bregma − 7 mm to − 8 mm, respectively) and
stored at − 80 °C. The samples were homogenized with
1 ml TRIzol reagent (Ambion, TX, USA) according to the
manufacturer’s instructions. Thus, the homogenized sam-
ples were centrifuged at 12000 g at 4 °C for 10 min, the
supernatant transferred to a new sterile Eppendorf tube
and incubated at room temperature for 5 min. Chloro-
form in a volume of 200 μl was added; the mixture was
vortexed and incubated again at room temperature for 2–
3 min. Following centrifugation at 12000 x g at 4 °C for
15 min the upper (clear) aqueous phase was transferred to
a new Eppendorf tube and was mixed with 500 μl of iso-
propanol and incubated for 10 min at room temperature.
After centrifuging the samples at 12000 x g at 4 °C for
10 min the supernatant was removed and 1 ml 75% etha-
nol was added to the precipitation. The samples were
again centrifuged at 7500 x g at 4 °C for 5 min, the super-
natant was removed, and 1 ml 75% ethanol was added.
After centrifuging samples at 7500 x g at 4 °C for 5 min,
the ethanol was removed, and the RNA pellets briefly
dried. The pellets were dissolved in 20 μl diethylpyrocar-
bonate treated-dH2O (DEPC-dH2O) and the samples
stored at − 80 °C until further processing. To determine
the quality of the samples 1–2 μl were used for optical
density (OD, 260/230 and 260/280 ratios) measurements.
The OD ratios were determined for all samples and ran-
domly repeated to evaluate the reliability of the measure-
ments (no significant difference was observed, data not
shown). Samples with the lowest RNA concentrations
were excluded from further analysis and thus both
MDMA and control groups consisted of 8 animals.
Two-two randomly selected samples were pooled in each
treatment group resulting in 4 pooled samples per brain
region and per treatment group. These samples
(altogether 24 samples) were sent to Service XS (Leiden,
Netherlands) for microarray analysis with the Illumina
(San Diego, CA, USA) RatRef-12 v1 beadarray expression
chip. Upon arrival, samples were once again subjects to a
purification process and quality control measurements
with Agilent Bioanalyzer and Nanodrop spectrophotom-
eter and one sample from the DR region was excluded
from further analysis due to degradation.
Data analysis
Raw microarray data were processed with beadarray
[84], preprocessCore [85] and puma [86] Bioconductor
[87] packages for R [88] as described in [89–91]. Briefly,
backgroundCorrect method used in the beadarray pack-
age was set to “minimum”, and “log = TRUE; n = 10”
variables were used for createbeadsummaryData method.
The normalization method used was the quantile
normalization method in the preprocessCore package.
Additionally, pumaComb, pumaDE, and write.rslts func-
tions with default settings were used. Changes were con-
sidered statistically significant when the MinPplr was
below 0.001. This strict criterion was necessary to
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reduce the number of false positive results to an accept-
able limit.
Heatmap visualization of the differences in gene ex-
pression was done using Multiexperiment Viewer Tool
[92, 93]. Genes with similar expression patterns are
grouped together with hierarchical clustering (Euclidean
distance, average linkage) [94].
GSEA was performed using GSEA version 3.1 from the
Broad Institute at MIT (http://www.broadinstitute.org/
gsea) [95, 96]. Gene sets (GMT format) were obtained
from the MSigDB for C5 category (GO gene sets) and in
addition, neuronal function related gene sets were selected
from the GO homepage (www.geneontology.org; [97])
manually. Gene identifiers used in the array dataset and
gene sets were gene symbols. The data set had 22,523 fea-
tures (Illumina probes), which were collapsed to gene
symbols (the median expression value was used for the
probe set). In these analyses, the gene sets analyzed were
restricted to those sets containing between 15 and 500
genes as recommended [98]. The t-test was used as the
metrics for ranking genes and gene set was chosen as the
permutation type because of the sample size in the study.
One thousand permutations were used to calculate
p-value with the seed of permutation set to 149. All other
basic and advanced fields were set to default. A normal-
ized enrichment score (NES) was calculated for each gene
set to represent the degree in which it was enriched in
one phenotype. The nominal p-value and the FDR corre-
sponding to each NES were calculated. A NES with a
nominal p-value < 0.05, FDR < 0.25 were considered sta-
tistically significant. Network visualization and analysis
using enrichment results was done using Cytoscape 2.8.3.
and its plugin “Enrichment Analyzer” with the following
cut-offs: similarity coefficient cut-off 0.1, p-value cut-off
0.05 and FDR cut-off 0.25 [98–100].
PCR validation
We have validated altogether 19 RNA products from the
original pooled samples with real-time PCR on Fluidigm
GEx array (San Francisco, CA, USA) using Taqman Gene
Expression assays for the appropriate RNAs obtained from
Applied Biosystems (Carlsbad, CA, USA) (for the full list
of validated genes see Additional file 4: Table S4). Each
sample was used in duplo following quality control mea-
surements (altogether three samples were excluded due to
degraded or insufficient amount of RNA). The validation
experiment was performed by Service XS (Leiden,
Netherlands). The Pearson correlation coefficients of the
fold change values of the quantile normalized microarray
and the housekeeper normalized PCR values were 0.619
and 0.610 for the 200 ng and 500 ng samples, respectively.
To provide support to our main conclusions, the array
and PCR fold change values of the extensively discussed
significant genes included in the validation study (Gria3,
Camk2g, Camk2b, Grin2b and Cnr1) in the FC and HC
are given in Additional file 5: Table S5.
Additional files
Additional file 1: Table S1. contains significantly up- or downregulated
genes compared to the control group in the three examined brain
region. (XLSX 123 kb)
Additional file 2: Table S2. contains individually selected GO terms for
GSEA analysis. (XLSX 42 kb)
Additional file 3: Table S3. contains the significantly enriched GO
terms selected by NES, FDR and nominal p-values (nomP) in the
examined brain regions. (XLSX 15 kb)
Additional file 4: Table S4. contains the genes validated with the
Fluidigm GEx PCR array and the used TaqMan assays. (XLSX 18 kb)
Additional file 5: TableS5. contains the fold change values of genes
validated and extensively discussed in the manuscript measured by
Illumina RatRef-12 v1 beadarrays and Fluidigm GEx PCR method after
normalization. (XLSX 10 kb)
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